Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch

doi:10.3748/wjg.v31.i26.109285

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (134)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-5)

Sum=106

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=19

Jul 14, 2025 (publication date) through Jul 12, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Jul 14, 2025; 31(26): 109285
Published online Jul 14, 2025. doi: 10.3748/wjg.v31.i26.109285

Open in New Tab Full Size Figure Download Figure

Figure 1 Workflow of the clinical trial. TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate.

Open in New Tab Full Size Figure Download Figure

Figure 2 Hepatitis B virus biomarkers dynamic changes between tenofovir amibufenamide group and tenofovir disoproxil fumarate group. A-E: The two groups showed consistent virological performance in terms of hepatitis B surface antigen (A), hepatitis B e antigen (B), hepatitis B virus (HBV)-DNA (C), HBV-RNA (D), HBV-microRNA-3 (E). TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; miR: MicroRNA.

Open in New Tab Full Size Figure Download Figure

Figure 3 Dynamic changes in lipid profiles between the tenofovir amibufenamide group and the tenofovir disoproxil fumarate group in chronic hepatitis B. A-E: The two groups exhibited comparable virological performance regarding cholesterol (A), low-density lipoprotein (B), high-density lipoprotein (C), triglycerides (D) and the triglycerides/high-density lipoprotein ratio (E). TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; CHOL: Cholesterol; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; TG: Triglycerides; TC: Total cholesterol.

Open in New Tab Full Size Figure Download Figure

Figure 4 Dynamic changes in renal function between the tenofovir amibufenamide group and the tenofovir disoproxil fumarate group in chronic hepatitis B. A: Creatinine (Cr); B: Cr clearance rate; C: Phosphorus. TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; Cr: Creatinine; CLCR: Creatinine clearance rate; PHOS: Phosphorus.

Citation: Zeng ZH, Liu JQ, Zhang M, Qiu CL, Xu ZY. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. World J Gastroenterol 2025; 31(26): 109285
URL: https://www.wjgnet.com/1007-9327/full/v31/i26/109285.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i26.109285